A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs Radafaxine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 14 Feb 2013 Actual end date added as 1 Apr 2007 as reported by ClinicalTrials.gov record.
- 22 May 2009 New trial record